Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$4.00 – $5.55
43% from low
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Revenue | $12.9M | $17.4M | $48.9M | $103.0M | $67.4M | $53.8M | $535.2M |
| Cost of revenue | $17.7M | $28.0M | $14.2M | $238.2M | $184.0M | $124.4M | $105.8M |
| Gross profit | −$4.9M | −$10.6M | $34.7M | −$135.2M | −$116.6M | −$70.6M | $429.4M |
| Gross margin | -37.9% | -60.7% | 71.0% | -131.3% | -172.9% | -131.3% | 80.2% |
| R&D | $41.7M | $43.2M | $113.8M | $815.9M | $62.5M | $115.7M | $153.0M |
| Operating income | −$72.8M | −$99.5M | −$124.0M | −$412.3M | −$249.5M | −$274.2M | $177.7M |
| EBITDA | −$69.9M | −$93.9M | −$123.1M | −$386.5M | −$209.4M | −$234.1M | $209.7M |
| Net income | −$71.2M | −$99.9M | −$129.1M | −$411.7M | −$249.0M | −$260.2M | $162.2M |
| Net margin | -553.5% | -573.5% | -264.0% | -399.8% | -369.4% | -484.0% | 30.3% |
| EPS (diluted) | -0.40 | -0.53 | -0.98 | -2.21 | -1.32 | -1.18 | 0.72 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $85M | $-0.42 | $-0.48–$-0.34 | 3 |
| 2027 | $136M | $-0.08 | $-0.10–$-0.07 | 1 |
| 2028 | $174M | $-0.64 | $-0.73–$-0.50 | 1 |
| 2029 | $181M | $-0.55 | $-0.63–$-0.43 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds CVAC.
No tracked institution reports a position in CVAC as of their last filing.
No one on the platform has traded CVAC yet.
| $1.4B |
| — |
| NKTRNektar Therapeutics | $65.39 | +2.73% | $1.3B | — |
| NVAXNovavax, Inc. | $9.36 | +5.41% | $1.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.9× sales vs its 35.8× historical median P/S.
Fair value ≈ $86.71 · price $4.66 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$CVAC aye I just realized my shares converted to $BNTX Didn’t know it was happening that soon - sahhhwwwweeet
View on StockTwits ↗I'm following the footprints on $CVAC—the 10-day VWAP is finally turning into a launchpad. 🏗️⚡ Setup: Perfect 8h pivot bottom; RSI is waking up from the dead (31) meaning the spring is officially loaded. Unusual Flow: 13F filings show Citadel and Susquehanna shifting heavily into calls (+136%) as the merger floor solidifies. 🏗️ Target: Clearing the $4.37 wall triggers the gap-fill to the $6.83 bull targets. 📈 Safety: Stop below the $4.07 structural floor. 🧱 The BioNTech moat is absorbing the competition. Don't fight the $101.88 exchange reference price. 🚢📉 #hovdid
View on StockTwits ↗$CVAC Volatility reflects uncertainty about how effectively strategy converts into measurable outcomes. Cash flow visibility will determine how patient investors remain. A series of confirmed wins might reduce the required risk premium. In short, this remains an execution‑driven story with meaningful but conditional upside.
View on StockTwits ↗$CVAC: One Last Momentum Play? 🎯 Action: Up +2.18% today as liquidity dries up ahead of the Jan buyout Catalyst: Compulsory acquisition in Jan 2026 will clean up remaining 13.2% of float Support: Rock solid at $3.80; Bulls holding the red trendline PT: Fair value sitting near the $5.43 analyst median for those still holding RSI is screaming oversold—watch for a final liquidity grab before it’s gone. 🔋💎 #hovdid
View on StockTwits ↗$BNTX and now all the trials will also have to show there is no shedding for approval Add more expenses for failure on top of $CVAC losses
View on StockTwits ↗$CVAC = loading time my friends !!!
View on StockTwits ↗$CVAC The P/E ratio will show its potential for improvement through synergies as early as next year. Most importantly, there will be no more internal legal disputes and 1,000 new patents for $BNTX . CureVac's expertise should help BioNTech get closer to the approval of mRNA-based cancer therapies. They are just one step away. This is a major undertaking, and I am convinced it will be worth significantly more than $1.25 billion in the long run.
View on StockTwits ↗@Tom2772 are there any numbers showing the combined value P/E etc since the $CVAC close? Do you think the combo improved the numbers?
View on StockTwits ↗$BNTX maybe it was just a bad time to take on more overhead and operational losses with $CVAC 🤔
View on StockTwits ↗@allan_ @Tintin1 $BNTX is way more over valued and just took on $CVAC for more losses
View on StockTwits ↗$BNTX $CVAC game of chicken with ACIP board meeting GLTA
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.